Programme Overview
Date | Event | Timing |
---|---|---|
Wednesday, June 3 Thursday, June 4 Thursday, June 4 Friday, June 5 Saturday, June 6 Sunday, June 7 Monday, June 8 |
Management Committee meeting Continuous Education Programme RIWC 2020 and NOK 2020 Shared Welcoming Ceremony Retina International Conference Retina International Conference Retina International General Assembly Incoming MC meeting (tentative) |
TBA 09:00 – 16:00 TBA See programme below See programme below TBA TBA |
Date | Event | Venue |
---|---|---|
Tuesday, June 2 Wednesday, June 3 Thursday, June 4 Friday, June 5 Saturday, June 6 Sunday, June 7 |
Arrival in Iceland Youth conference Horse Riding Tour / Workshop / Welcome Ceremony Lecture / Congress / Concert Retina Congress / Gala Dinner Optional activities |
Studenthostel Hamrahlíð 17 / Downtown Íshestar / Hamrahlíð 17 / Eldborg, Harpa Hamrahlíð 17 / Harpa Harpa concert hall / Kolabrautin x |
Thursday June 4th | ||||
RIWC 2020 | View NOK 2020 Programme | |||
Hall | Norðurljós | Björtuloft | Eldborg | |
08:00-08:30 | ||||
08:30-10:00 | ||||
10:00-10:30 | ||||
10:30-11:00 | ||||
11:00-12:00 | ||||
12:00-13:30 | ||||
13:30-15:00 | ||||
15:00-15:30 | ||||
15:30-17:00 | ||||
17:00-17:30 | ||||
17:30-19:00 | 17:00 – 19:00 Welcoming ceremony. | |||
17:30-18:30 | K.1.1.Key note: The development of a bioelectronic implant for sight restoration for retinal degenerations. Prof. Mark S. Humayun University of Southern California, LA, USA |
Friday June 5th | |||
RIWC 2020 | View NOK 2020 Programme | ||
Hall | Norðurljós | Björtuloft | |
07:40-08:20 | |||
08:30-10:00 | P.2.1 Age related macular Degeneration Moderator: Dr. Øystein Kalsnes Jørstad, Oslo University | L.2.1 Retinal degenerations. Clinical aspects. Moderator: Dr. Prof. Elise Heon, The Hospital for Sick Children, Toronto, Canada | |
08:30 - 08:50: A systems level investigation on AMD: Insights from the European EYERISK project Speaker: Professor Marius Ueffing, Centre for Ophthalmology, University Medical Center, Tuebingen, Germany | 08:30 – 08:50: Clinical aspects of IRD Speaker: Prof. Dr. Elise Heon The Hospital for Sick Children, Toronto, Canada | ||
08:50 - 09:05: AMD research at Oslo University Hospital: from LUCAS to compounding pharmacy Speaker: Professor Morten Carstens Moe, Oslo University Hospital, Oslo, Norway | 08:50 - 09:10: Clinical aspects of inherited macular degenerations. Speaker: Dr. Line Kessel, Department of Ophthalmology, Rigshospitalet, Copenhagen, Denmark. | ||
09.05.- 09:15: Off-label use of Avastin: Scandinavian disparities Speaker: Tomas Bro, MD, PhD, Höglandssjukhuset, Eksjö, Sweden | 09:10 - 09:30 Usher syndrome and similar syndromic forms of IRD. Speaker: prof. Dr. Hélène Dollfus, CARGO, Hôpitaux Universitaires de Strasbourg, France | ||
09:15-09:25: The risk of extending AMD treatment Speaker: David Epstein, MD, PhD. Sankt Erik Eye Hospital, Karolinska Institute, Stockholm, Sweden | |||
09:25 - 09:35 The Swedish Macula Register Speaker: Inger Westborg, MD, PhD., Uppsala University Hospital, Uppsala, Sweden | |||
09:35 - 09:50 AMD Epidemiology and Genetics. What is important! Speaker: Prof. emeritus Friðbert Jónasson, University of Iceland, Iceland: | 09:30 - 09:50: The socio-economic impact of IRDs Speaker: Dr. Orla Galvin, Retina International, Dublin, Ireland | ||
09:50 - 10:00: QnA | 09:50 – 10:00 QnA. | ||
10:00-10:30 | Coffee break | ||
10:30-11:30 | P.2.2 Assessment of Endpoints in clinical studies. Moderators Dr. Cecilie Bredrup, Bergen, Norway and Prof. Sten Kjellström, Lund, Sweden. | L.2.2 Retinal degenerations - the genetics. Moderator: Prof. Jón Jóhannes Jónsson, national University Hospital, Reykjavík, Iceland. | |
10:30 – 10:50: How to measure the effects of gene therapy on meaningful vision for patients Speaker: Prof. Michael Larsen Department of Ophthalmology, Rigshospitalet, Copenhagen, Denmark: | 10:30 – 10:50: Pattern of inheritance - easy to understand. Speaker: Dr. Eirný Þórólfsdóttir National University Hospital, Reykjavík, Iceland. | ||
10:50 – 11:10 Paediatric specificities in trials Speaker: Prof. Dr. Elise Heon, MD, The Hospital for Sick Children, Toronto, Canada | 10:50 – 11:10: Understanding the results - a difficult task. Speaker: Prof. Jón Johannes Jónsson, national University Hospital, Reykjavík, Iceland. | ||
11:10 – 11:30: Developing Patient Relevant Outcomes in Gene Therapy Trials: The Novel Functional Vision Endpoint, the Multi-luminance Mobility Test (MLMT) Speaker: Dr. Daniel Chung, DO, MA, Spark Therapeutics, Philadelphia, USA | 11:10 – 11:20 Lessons from Iceland on the diversity of genetic causes. Speaker: Daníel Þorsteinsson | ||
11:20 – 11:30: Accessing Genetic Testing for IRDs: The Patient Perspective. Speaker: Avril Daly, Retina International, Dublin, Ireland | |||
11:30-12:00 | K.2.1 Keynote: Scientific results, a rollercoaster between hope and deception Speaker: Christina Fasser, president of Retina International, Zurich (Switzerland) | ||
12:00-13:30 | Lunch | ||
13:30-14:00 | K.2.2 Keynote: Phenotyping and Genotyping in inherited retinal diseases. Speaker: Prof. Bart Leroy, University of Ghent, Gent, Belgium | ||
14:00-15:00 | P.2.3 Phenotyping and Genotyping in IRD. Moderators: Josephine Prener Holta | L.2.3 Basics of stem cell and gene-based therapies. Moderator: Prof. Kapil Bharti. National Eye Institute, Bethesda, USA | |
14:00 – 14:10: Natural history and clinical characterization of patients with retinitis pigmentosa caused by mutations in the PRPF31 gene Speaker: Dr. Kristian Lisbjerg, Copenhagen University Hospital, Denmark | 14:00- 14:20 Overview of on-going clinical trials with stem cells Speaker: Prof. Goran Petrovski | ||
14:10 – 14:20: Genetic basis and phenotypic characterization of Danish patients with Achromatopsia. Speaker: Dr. Mette K.G. Andersen, Copenhagen University Hospital, Rigshospitalet-Glostrup, Copenhagen, Denmark | 14:20 – 14;35 Stem cell trial on Retinitis pigmentosa. Speaker: Prof. Kapil Bharti. National Eye Institute, Bethesda, USA | ||
14:20 – 14:30 Whole exome sequencing in the diagnosis of hereditary retinal disorders: A clinical perspective Speaker: Prof. Ragnhild janson Wives tad, Hauk eland University Hospital, Norway | 14:35 – 14:50 Clinical trial in opto-genetics. Speaker: Prof. Isabelle Audo, INSERM, Paris, France | ||
14:30 – 14:50 ERN-EYE a booster for patients care and research for Rare Eye Diseases in Europe Speaker: prof. Dr. Hélène Dollfus, CARGO, Hôpitaux Universitaires de Strasbourg, France: | 14:50 – 15:00 How to discriminate between real treatments offers and quacks. Speaker: Martin Smedstad Oslo, Norway. | ||
14:50 – 15:00 QnA | |||
15:00-15:30 | Coffee break | ||
15:30-16:00 | K.2.3 Keynote: Innovations in Ophthalmology. Prof. Eugene De Juan University of California, San Francisco, USA. | ||
16:00-17:00 | P.2.4. Innovations in Ophthalmology Moderators: Christina Fasser and Prof. Einar Stefánsson. | L.2.4 Rehabilitation and mobility training. Moderators: Vala Jóna Garðarsdóttir and Rosa María Hjörvar Iceland. | |
Speakers: Dr. Sabri Markabi, MD Senior vice president of Research and Development and Chief Medical Officer of Alcon Laboratories, Inc., a subsidiary of Alcon, Inc., the world’s largest eye care company. Prof. Einar Stefánsson, National University Hospital in Iceland. Kathrine A. High, Emeritus co-founder, president and chief scientific officer of Spark. To be confirmed. | 16:00 - 16:15: Mobility training and mobility tools Speaker: Vala Jóna Garðarsdóttir. National institute for the blind in Iceland. | ||
16:15 – 16:30 Reading with auxiliary aids Speaker: Rósa María Hjörvar. PhD student in Literature at the University of Iceland | |||
16:30-16:45: The assistive technology, aps etc. Speakers: Baldur Snær Sigurðsson and Hlynur Þór Agnarsson | |||
16:45 - 17:00: Coping with visual and hearing impairment: Speakers: Halla Dís Hallfreðsdóttir and Elín Yr. Hafdisardóttir Arnardóttir. |
Saturday June 6th | |||
RIWC 2020 | View NOK 2020 Programme | ||
Hall | Norðurljós | Björtuloft | |
08:00-08:30 | |||
08:30-10:00 | P.3.1 Preparing for clinical trials in IRD. Moderator: Prof. Michael Larsen. Speakers to be confirmed | L.3.1 Clinical trials and therapies from a patient’s perspective. Moderator: Martin Smedstad, Oslo, Norway. | |
08:30 – 08:50 Overview and future on on-going clinical trials Speaker Prof. Dr. Elise Heon, MD, The Hospital for Sick Children, Toronto, Canada | |||
08:50 – 09:10: RPE65 - the first gene therapy on the market Speaker: Dr. Daniel Chung, DO, MA, Spark Therapeutics, Philadelphia, USA. | |||
09:10 – 09:30 Oligonucleotides - a hope for all? Speaker: Prof. Bart Leroy, Gent University, Ghent, Belgium | |||
09:30 – 09:50 My personal experience with a clinical trial Speaker: to be confirmed. | |||
10:00-10:30 | Coffee break | ||
10:30-12:00 | P.3.2 Stem cells and cell-based therapies of retinal diseases. Moderator Dr. Goran Petrovski, Oslo, Norway. | L 3.2 Retina International - the global challenges Moderator: Kristinn Halldor Einarsson, Iceland | |
10;30 – 10:45: Initiating a Phase I/IIa clinical trial for an autologous iPS cell therapy for macular degeneration: from bench-to-bedside. Speaker: Prof. Kapil Bharti (NIH/NEI), Bethesda, USA. | Speakers:Christina Fasser.Avril Daily. Other speakers to be confirmed. | ||
10:45 – 11:00 Towards stem cell-based therapies in retinal degenerations Speaker: Anders Kantar (Stockholm, Sweden | |||
11:00 – 11:30 Subretinal implantation of primary human RPE cells in minipig eyes. Speaker: Dr. Goran Petrovski, Oslo, Norway. | |||
11:30 – 12:00 Epigenetic characterization during differentiation from iPS to RPE cells in AMD. Speaker: Dr. Cristina Zibetti (Oslo, Norway) | |||
12:00-13:30 | Lunch | ||
13:30-14:00 | K.3.1 Keynote: Hope without Hype: Gene-based Therapies for Inherited Retinal Diseases Speaker: Prof. Artur Cideciyan, University of Pennsylvania, Philadelphia, USA. | ||
14:00-15:00 | P.3.3 Gene based therapies of retinal diseases. Moderator Eeva-Marja Sankila, MD, PhD, Helsinki University Hospital, Helsinki, Finland | L.3.4 Programme in islandic for the public. Moderator: Dr. Sigríður Másdóttir, Reykjavík, Iceland. | |
14;00 – 14:15 CPK850 gene therapy in RLPB1 patients. Speaker: Prof. Anders Kantar, Karolinska Institute, Stockholm, Sweden | |||
14:15 – 14:30 Retinal gene therapy trials - investigators point of view Speaker: EevaMarja Sankila, MD, PhD, Helsinki University Hospital, Helsinki, Finland | |||
14:30 – 14:45 Retinal gene therapy in choroideremia patients - surgical aspects. Speaker: Prof. Illka Immonen, Helsinki University Hospital, Helsinki, Finland | |||
14:45 – 15:00 Gene therapy of Usher syndrome. Speaker: Prof. Isabelle Audo, Institute de la Vision, Paris, France | |||
15:00-15:30 | Coffee Break | ||
15:30-17:00 | K.3.3 What the future holds: Panel discussion (AMD, IRD, genetics, Innovation) | ||
17:00-17:30 | K.3.4 What have we learned? Speaker: Prof Emeritus Gerald G. Chader, Los Angeles, USA | ||
17:30-18:00 | Closing Ceremony |